title: Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*.
abstract: Acral erythema is considered a frequent complication of chemotherapy administration. The bullous variant of chemotherapy-induced acral erythema, or bullous acral erythema, occurs less commonly. The condition typically begins with acral dysesthesias and produces symmetric erythema that blisters and eventually desquamates. Overall, 32 cases of bullous acral erythema have been described in the literature, including 21 cases associated with cytarabine administration and 11 cases attributed to methotrexate. We describe a 61-year-old woman with diffuse large B-cell lymphoma in whom bullous acral erythema developed after she received cytarabine and methotrexate. The clinical presentation was unusual, as it was characterized by vesicles in an annular configuration suggestive of linear immunoglobulin A bullous disease. Histopathology revealed a pauci-inflammatory subepidermal bulla that was similar to previously reported cases of bullous acral erythema. We suggest that bullous acral erythema represents an important diagnostic consideration in the differential diagnosis of pauci-inflammatory subepidermal blistering in patients who have recently received chemotherapy.
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Joshua O
authors.initials: JO
authors.lastname: Podjasek
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Camilleri
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001768:Blister / Q000139:chemically induced* / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D060831:Hand-Foot Syndrome / Q000473:pathology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008727:Methotrexate